2024-03-29T09:54:27Z
https://niigata-u.repo.nii.ac.jp/oai
oai:niigata-u.repo.nii.ac.jp:00022173
2022-12-15T03:52:32Z
453:456
471:537:538:1196
Recent advances in the treatment of adult ALL(20th Meeting of the Niigata Society of Hematologic Neoplasm The Ten-year Anniversary Symposium : Progress in Hematologic Neoplasm over the Ten Years)
成人急性リンパ性白血病の治療(第20回新潟造血器腫瘍研究会十周年記念シンポジウム : 造血器腫瘍十年の歩み)
成人急性リンパ性白血病の治療(第20回新潟造血器腫瘍研究会十周年記念シンポジウム : 造血器腫瘍十年の歩み)
林, 直樹
134749
荒川, 正昭
134750
Adult ALL
treatment
L-series
成人急性リンパ性白血病
治療法の進歩
The treatment of adult acute lymphocytic leukemia (ALL) has been still unsatisfactory because of high relapsing rate after complete remission (CR) and easy acquirement of multiple drug resistance, although that of childhood ALL has been improved remarkably. In order to keep long-term CR, more intensive induction, consolidation and maintenance therapies have to be introduced. Based on this therapeutic concept, Memorial Sloan Kettering's group has introduced L-series protocol and reported favorable clinical results. We have tried modified L-10M protocol as our standard regimen since 1985. All 5 patients treated so far have achieved CR, but relapse in central nerve system (CNS) was found in 2 cases after cessation of intrathecal methotrexate injection, which suggested the importance of prophylactic treatment for CNS leukemia. In addition to the progress of chemotherapeutic strategy, the development of diagnostic methods, more advanced supportive therapies and bone marrow transplantation shoud be considered for improving clinical results. Finally, attempts for developing new chemotherapeutic agents, new treatment programs and novel immunotherapy (application of biological response modifiers etc) will be necessary for getting better clinical results in adult ALL.
departmental bulletin paper
新潟医学会
1990-07
application/pdf
新潟医学会雑誌
7
104
546
551
新潟医学会雑誌
AN00182415
00290440
https://niigata-u.repo.nii.ac.jp/record/22173/files/104(7)_546-551.pdf
jpn